Photos by Kyle LaHucik
August 30, 2022 06:19 AM EDTUpdated September 1, 10:59 AM
People
R&D

#ESC22: In re­turn to ‘big chron­ic dis­eases,’ Eu­rope’s car­dio con­fab show­cas­es mixed bag of da­ta drops

Kyle LaHucik

Senior Reporter

BARCELONA — For the first time dur­ing Covid-19, 30,000 car­di­ol­o­gists, bio­phar­ma lead­ers and tri­al in­ves­ti­ga­tors met in per­son for the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy Con­gress. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times